Literature DB >> 10328575

Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections.

N G Singer1, W J McCune.   

Abstract

Most rheumatology textbooks lack adequate recommendations for specific immunization of patients with rheumatic diseases, especially those treated with immunosuppressive medications. The authors wish to alert clinicians to issues pertinent to immunization of immunosuppressed rheumatology patients. By elucidating deficiencies in the current literature, the authors hope to identify future directions for clinical investigation and to increase the rates of effective immunization against vaccine preventable diseases. In addition to focusing on immunizations, this article also discusses Pneumocystis carinii prophylaxis in immunosuppressed patients with rheumatic diseases and screening that clinicians should consider before beginning administration of immunosuppressive agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328575     DOI: 10.1097/00002281-199905000-00004

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

Review 1.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

Review 2.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

3.  Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.

Authors:  Thomas G Cotter; Nicola Gathaiya; Jelena Catania; Edward V Loftus; William J Tremaine; Larry M Baddour; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn; Andrew H Limper; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

Review 4.  [Pneumocystis jiroveci pneumonia (PcP) in patients with rheumatic diseases: case report and review].

Authors:  B Bertisch; C Ruef
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

Review 5.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.

Authors:  Gabriela Schmajuk; Kashif Jafri; Michael Evans; Stephen Shiboski; Milena Gianfrancesco; Zara Izadi; Sarah L Patterson; Ishita Aggarwal; Urmimala Sarkar; R Adams Dudley; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2018-11-03       Impact factor: 5.532

7.  Acute Pneumocystis jirovecii Pneumonia Due to Absolute Lymphopenia.

Authors:  Eric Hilker; Sachin M Patil; Rodger Wilhite; Zach Holliday
Journal:  Cureus       Date:  2022-03-02

8.  Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.

Authors:  Kiyoshi Migita; Toru Arai; Naoki Ishizuka; Yuka Jiuchi; Yasuharu Sasaki; Yasumori Izumi; Tetsuyuki Kiyokawa; Eiichi Suematsu; Tomoya Miyamura; Hiroshi Tsutani; Yojiro Kawabe; Ryutaro Matsumura; Shunsuke Mori; Shiro Ohshima; Shigeru Yoshizawa; Kenji Kawakami; Yasuo Suenaga; Hideo Nishimura; Toyohiko Sugimoto; Hiroaki Iwase; Hideyuki Sawada; Haruhiro Yamashita; Shigeyuki Kuratsu; Fumitaka Ogushi; Masaharu Kawabata; Toshihiro Matsui; Hiroshi Furukawa; Seiji Bito; Shigeto Tohma
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.